TauRx reportedly in partnership talks for Rember

The largely unknown TauRx has been basking in the limelight of some startling efficacy data for its experimental Alzheimer's drug--Rember. TauRx was founded by research scientists at Aberdeen University who opted to base the company in Singapore, where officials were willing to provide funding without the kind of stinging equity bite the UK venture crowd was demanding.

Now TauRx officials tell The Times that ongoing discussions may soon lead to new partnerships for the fledgling biotech. The IP for Rember is entirely owned by TauRx, but that may soon change.

- read the article from The Times

Suggested Articles

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.